AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...
Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...
5don MSN
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback